Asset Details
Do you wish to reserve the book?
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Do you wish to request the book?
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
2011
Overview
Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010.
Methods: Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded.
Results: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing–remitting MS patients (n = 901), mean Expanded Disability Status Scale (EDSS, −10.7%), Multiple Sclerosis Severity Scale (MSSS, −20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical −9.9%, psychological −13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials.
Conclusions: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.
Publisher
SAGE Publications,Sage Publications,Sage Publications Ltd
Subject
/ Adult
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Biological and medical sciences
/ Female
/ Humans
/ Immunologic Factors - adverse effects
/ Immunologic Factors - therapeutic use
/ Leukoencephalopathy, Progressive Multifocal - chemically induced
/ Leukoencephalopathy, Progressive Multifocal - mortality
/ Male
/ MEDICIN
/ MEDICINE
/ Multiple Sclerosis, Chronic Progressive - diagnosis
/ Multiple Sclerosis, Chronic Progressive - drug therapy
/ Multiple Sclerosis, Chronic Progressive - mortality
/ Multiple Sclerosis, Relapsing-Remitting - diagnosis
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - mortality
